Skip to main content Back to Top


Hydroxychloroquine Sulfate Tablets

Products Affected - Description

    • Hydroxychloroquine sulfate tablet, Ranbaxy, 200 mg, 100 count, NDC 63304-0296-01
    • Hydroxychloroquine sulfate tablet, Ranbaxy, 200 mg, 500 count, NDC 63304-0296-05

Reason for the Shortage

    • Concordia acquired Plaquenil tablets from Covis in April 2015.
    • Ranbaxy has hydroxychloroquine on shortage due to a regulatory issue.
    • Sandoz states the hydroxychloroquine shortage was due to increased demand.
    • Zydus has hydroxychloroquine tablets available to current customers.
    • West-Ward discontinued hydroxychloroquine tablets in September 2014.

Available Products

    • Plaquenil tablet, Concordia, 200 mg, 100 count, NDC 24987-0562-10
    • Hydroxychloroquine sulfate tablet, Mylan, 200 mg, 100 count, NDC 00378-0373-01
    • Hydroxychloroquine sulfate tablet, Sandoz, 200 mg, 100 count, NDC 00781-1407-97
    • Hydroxychloroquine sulfate tablet, Sandoz, 200 mg, 500 count, NDC 00781-1407-52
    • Hydroxychloroquine sulfate tablet, Zydus, 200 mg, 100 count, NDC 68382-0096-01

Estimated Resupply Dates

    • Ranbaxy has product on long-term back order and the company cannot estimate a release date.
    • All other suppliers have product available.


Updated May 26, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 5, 2014 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins